Recent results with adavosertib in ovarian cancer could signal future positive results, given the number of trials using the targeted therapy with the PARP inhibitor olaparib.
New results involving the Wee1 inhibitor adavosertib brought improved survival benefits in a hard-to-treat type of ovarian cancer, but trials in the pipeline suggest the positive findings could be just the beginning.
Investigators reported last week that adavosertib to the chemotherapy gemcitabine reduced the risk of disease progression and death in women with relapsed, platinum-resistant or refractory ovarian cancer. The phase 2 results appeared in The Lancet.
The study involved 124 women, of whom 99 had high-grade serious ovarian cancer. They were randomized 2:1 to receive adavosertib plus gemcitabine (65 patients) or placebo plus gemcitabine (34 patients). Another 25 women were placed in an exploratory cohort. After randomization, 5 women (4 taking the study drug, 1 in the placebo group), were found ineligible and did not receive treatment. Median age for treated patients was 62 years.
Progression-free survival was 4.6 months in the group taking adavosertib, compared with 3.0 months for the group taking gemcitabine only, for a hazard ratio of 0.55 (95% CI, 0.35-.90, P = .015). An accompanying editorial noted the dose-response relationship and relatively manageable toxicity.
“This study realizes the potential of targeting the cell cycle derangement present in a substantial subpopulation of patients with resistant ovarian cancer," the editorial stated. “The development of rapid immunohistochemical or circulating biomarkers to identify this subpopulation could herald the more widespread use of cell cycle targeting therapies like adavosertib earlier in the disease course.”
The trial ran from September 2014 to May 2018, with a start date just before the PARP inhibitor olaparib was approved for the treatment of ovarian cancer for patients with germline BRCA ovarian cancer who had received at least 3 prior lines of therapy. PARP inhibitors, and olaparib in particular, have proven to be game-changers in BRCA-driven ovarian cancer.
According to the National Cancer Institute, there are now several trials under way involving adavosertib with olaparib. Since 2014, olaparib has received FDA approval in other indications for ovarian cancer, including a May 2020 approval for maintenance treatment, either as a monotherapy or in combination with bevacizumab.
According to the NCI website, trials involving adavosertib and olaparib in ovarian cancer and other solid tumors include:
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Most Patients With Mucinous Ovarian Cancer Don't Need Perioperative GI Endoscopy
April 12th 2024A new study suggests routine gastrointestinal (GI) endoscopy is not needed for most patients with mucinous ovarian cancer in the perioperative setting due to a lack of statistically significant overall survival benefits.
Read More